Skip to main content
RXRX
NASDAQ Life Sciences

Recursion Q2 Revenue Misses, Loss Wider Than Expected; Cuts Expense Outlook

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.03
Mkt Cap
$1.757B
52W Low
$2.77
52W High
$7.18
52W Position info
9.4% above low
Off High info
58% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RXRX is trading near its 52-week low of $2.77 (9.4% above the low).

Summary

Recursion's Q2 revenue of $7.3M missed consensus by 39%, driven by declining collaboration revenue from Roche/Genentech as projects completed. Net loss of $131M was wider than the $119M analysts expected, despite cost cuts. The company lowered its 2026 cash operating expense guidance to under $375M from under $390M, extending its cash runway into early 2028. Two key pipeline catalysts are on deck for 2H26: the start of a Phase 1/2 trial for REC-7735 and a registrational path update for REC-4881. The revenue miss and wider loss raise concerns about near-term growth, but the extended runway and upcoming catalysts could shift sentiment if positive.

At the time of this announcement, RXRX was trading at $3.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.77 to $7.18. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.65 info
Change: -$1.17 (-31%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.83
Real-time Price: $2.65 info
Change: -$1.18 (-31%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.65 info
Change: -$1.15 (-30%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:25 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.65 info
Change: -$1.18 (-31%) info
Market Cap: $1.696B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.65 info
Change: -$1.52 (-36%) info
Market Cap: $1.696B info